--- title: "Maze Therapeutics (MAZE) news: IPO and offering" url: "https://aibio.space/companies/maze-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "MAZE IPO and offering news: Maze Therapeutics prices IPO of 8,750,000 shares at $16.00. Maze Therapeutics, Inc. (NASDAQ: MAZE), United States." --- MAZE Maze Therapeutics, Inc. NASDAQ · United States # Maze Therapeutics (MAZE) news MAZE IPO and offering news Financings · 2026-10-16 ## [Maze Therapeutics swaps 2,776,007 Frazier-held shares for pre-funded warrants](https://aibio.space/news/maze-therapeutics-swaps-2-776-007-frazier-held-shares-pre-funded/) The exchange leaves Maze with 53,931,889 shares of common stock outstanding as of October 16, 2026. ## Latest Maze Therapeutics news 1. 2026-04-22 Financings [Maze Therapeutics prices $150 million stock and pre-funded warrant offering](https://aibio.space/news/maze-therapeutics-prices-150-million-stock-pre-funded-warrant-offering/) Maze Therapeutics, Inc. is selling 5,540,000 shares at $23.50 each and pre-funded warrants for 850,000 shares. Leerink Partners LLC is sole underwriter, and dilution to new investors is $14.40 per share. 2. 2026-02-04 Debt Financing [Maze Therapeutics draws $40.0 million under Hercules term loan facility of up to $200.0 million](https://aibio.space/news/maze-therapeutics-draws-40-0-million-under-hercules-term-loan-facility/) Maze received an initial $40.0 million term loan and says net proceeds were approximately $38.4 million. Up to $160.0 million more is available if conditions are met. It also ended its Banc of California loan. 3. 2026-02-04 Distress [Maze Therapeutics signs Hercules loan of up to $200.0 million, draws $40.0 million](https://aibio.space/news/maze-therapeutics-signs-hercules-loan-up-200-0-million-draws-40-0/) The senior secured facility matures February 1, 2031. Maze ended its Banc of California loan agreement in connection with the deal. 4. 2025-01-31 Financings [Maze Therapeutics prices IPO of 8,750,000 shares at $16.00](https://aibio.space/news/maze-therapeutics-prices-ipo-8-750-000-shares-16-00/) Maze priced at $16.00 and expects net proceeds of approximately $127.7 million. The company reported a net loss of $100.4 million for 2023 and has no product approved for sale. 5. 2025-01-07 Financings [Maze Therapeutics files for IPO of common stock, seeks Nasdaq listing as MAZE](https://aibio.space/news/maze-therapeutics-files-ipo-common-stock-seeks-nasdaq-listing-maze/) Maze's IPO filing names four underwriters and leaves the share count and price range blank. The nine months to September 30, 2024 include $167,500 thousand of license revenue. ## Maze Therapeutics at a glance - **Ticker**: MAZE - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $411.1 million ### Related companies - [Integrated BioPharma](https://aibio.space/companies/integrated-biopharma/) OTC: INBP - [Neumora Therapeutics](https://aibio.space/companies/neumora-therapeutics/) NASDAQ: NMRA - [Context Therapeutics](https://aibio.space/companies/context-therapeutics/) NASDAQ: CNTX - [Protagenic Therapeutics](https://aibio.space/companies/protagenic-therapeutics/) OTC: PTIX - [MannKind](https://aibio.space/companies/mannkind/) NASDAQ: MNKD - [Biohaven](https://aibio.space/companies/biohaven/) NYSE: BHVN - [Pacira BioSciences](https://aibio.space/companies/pacira-biosciences/) NASDAQ: PCRX - [Telomir Pharmaceuticals](https://aibio.space/companies/telomir-pharmaceuticals/) NASDAQ: TELO ### Also on NASDAQ - [Indaptus Therapeutics](https://aibio.space/companies/indaptus-therapeutics/) INDP - [Erasca](https://aibio.space/companies/erasca/) ERAS - [MiniMed Group](https://aibio.space/companies/minimed/) MMED - [4D Molecular Therapeutics](https://aibio.space/companies/4d-molecular-therapeutics/) FDMT - [Champions Oncology](https://aibio.space/companies/champions-oncology/) CSBR - [Latigo Biotherapeutics](https://aibio.space/companies/latigo-biotherapeutics/) LTGO ## Maze Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | | [$167.5 million](https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/) | | Research and development | [$108.4 million](https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/) | [$83.5 million](https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/) | | Net income (loss) | [-$131.1 million](https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/) | [$52.2 million](https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/) | | Cash from operations | [-$111.9 million](https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/) | [$76.0 million](https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/) | | Cash and equivalents | [$189.2 million](https://www.sec.gov/Archives/edgar/data/1842295/000119312526344903/) | [$196.8 million](https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/) | | Short-term investments | [$152.7 million](https://www.sec.gov/Archives/edgar/data/1842295/000119312526344903/) | | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $202.6 million, plus short-term investments of $208.4 million, $411.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Maze Therapeutics When did Maze Therapeutics go public? Our latest story on this, dated Jan 31, 2025: "Maze Therapeutics prices IPO of 8,750,000 shares at $16.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/maze-therapeutics-prices-ipo-8-750-000-shares-16-00/). Has Maze Therapeutics raised money recently? Our latest story on this, dated Apr 22, 2026: "Maze Therapeutics prices $150 million stock and pre-funded warrant offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/maze-therapeutics-prices-150-million-stock-pre-funded-warrant-offering/). What is the ticker symbol of Maze Therapeutics? Maze Therapeutics, Inc. trades under the ticker MAZE on NASDAQ. Where is Maze Therapeutics listed? Maze Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Maze Therapeutics? The SEC Central Index Key (CIK) for Maze Therapeutics, Inc. is 1842295. Its filings are on SEC EDGAR. How many shares does Maze Therapeutics have outstanding? 55,549,168 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Maze Therapeutics listed under? Our directory records Maze Therapeutics, Inc. under United States. What does Maze Therapeutics do? Our directory classifies Maze Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Maze Therapeutics? The ISIN recorded for Maze Therapeutics, Inc. is US5787841007. Does aibio.space cover Maze Therapeutics? aibio.space lists Maze Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Maze Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Maze Therapeutics profitable? Maze Therapeutics, Inc. reported a net loss of $131.1 million for the fiscal year ended Dec 31, 2025, and used $111.9 million of cash in operations, per its annual report to the SEC. How much does Maze Therapeutics spend on research and development? $108.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Maze Therapeutics have? $411.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Maze Therapeutics (MAZE) stock news? Our latest story on Maze Therapeutics, dated Oct 16, 2026: "Maze Therapeutics swaps 2,776,007 Frazier-held shares for pre-funded warrants". The exchange leaves Maze with 53,931,889 shares of common stock outstanding as of October 16, 2026. [Source](https://aibio.space/news/maze-therapeutics-swaps-2-776-007-frazier-held-shares-pre-funded/). ## Investor discussion: Maze Therapeutics Members talk about Maze Therapeutics (MAZE). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Maze Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-16 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1842295/000119312526424067/d445364d8k.htm) 2. 2026-04-22 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1842295/000119312526170687/d15217d424b5.htm) 3. 2026-02-04 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03). [Source](https://www.sec.gov/Archives/edgar/data/1842295/000119312526037747/d34522d8k.htm) 4. 2026-02-04 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1842295/000119312526037831/d19492ds3asr.htm) 5. 2025-09-11 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1842295/000119312525200760/d90404dex991.htm) 6. 2025-01-31 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1842295/000119312525018482/d769642d424b4.htm) 7. 2025-01-07 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1842295/000119312525002851/d769642ds1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:MAZE on TradingView](https://www.tradingview.com/symbols/NASDAQ-MAZE/). ## SEC filings and registration - **SEC name**: Maze Therapeutics, Inc. - **CIK**: 1842295 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: MAZE (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: 6508505070 - **Shares outstanding**: 55,549,168 as of 2026-08-05 (10-Q filed 2026-08-11) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1842295/000119312526424067/d445364d8k.htm) filed 2026-10-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1842295/000119312526354092/d135740d8k.htm) filed 2026-08-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1842295/000119312526344903/maze-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/maze-20260811.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1842295/000119312526265858/d110541d8k.htm) filed 2026-06-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1842295/000119312526237199/d909749d8k.htm) filed 2026-05-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1842295/000119312526219430/maze-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1842295/000119312526219398/maze-20260512.htm) filed 2026-05-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001842295), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Maze Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MAZE, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Maze Therapeutics, Inc. - **Ticker**: MAZE - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US5787841007 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-MAZE/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/maze-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Maze Therapeutics (MAZE) news: IPO and offering", 2026-10-31, https://aibio.space/companies/maze-therapeutics/